(Q38040527)

27 August 2017

Advances with vaccination against Neisseria meningitidis (English)

1 reference

27 August 2017

Neisseria meningitidis

1 reference

1

Ray Borrow

1 reference

27 August 2017

4 September 2012

1 reference

Tropical Medicine and International Health

27 August 2017

1 reference

27 August 2017

17

1 reference

27 August 2017

12

1 reference

27 August 2017

1478-1491

1 reference

Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles

27 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Rapid genetic grouping of factor h-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Meningococcal disease and prevention at the Hajj.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Induction of immunological memory in UK infants by a meningococcal A/C conjugate vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vacc

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Critical appraisal of a quadrivalent CRM(197) conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo) in the context of treatment and prevention of invasive disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Genetics and evolution of Neisseria meningitidis: importance for the epidemiology of meningococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

NadA, a novel vaccine candidate of Neisseria meningitidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

NadA diversity and carriage in Neisseria meningitidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Complement deficiency states and meningococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Meningococcal group C and w135 immunological hyporesponsiveness in african toddlers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Vaccine potential of the Neisseria meningitidis 2086 lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

A universal vaccine for serogroup B meningococcus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Kinetics of Antibody Production to Group A and Group C Meningococcal Polysaccharide Vaccines Administered during the First Six Years of Life: Prospects for Routine Immunization of Infants and Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Human immunity to the meningococcus. I. The role of humoral antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Manson Lecture. Meningococcal meningitis in Africa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Global epidemiology of meningococcal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

The Neisseria meningitidis macrophage infectivity potentiator protein induces cross-strain serum bactericidal activity and is a potential serogroup B vaccine candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Development of vaccines against meningococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Invasive meningococcal capsular group Y disease, England and Wales, 2007-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

A novel phase variation mechanism in the meningococcus driven by a ligand-responsive repressor and differential spacing of distal promoter elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Where is the meningitis belt? Defining an area at risk of epidemic meningitis in Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Meningococcal PorA/C1, a channel that combines high conductance and high selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Conquering the meningococcus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Epidemic meningitis, meningococcaemia, and Neisseria meningitidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

An outer membrane receptor of Neisseria meningitidis involved in zinc acquisition with vaccine potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Advances in the development of vaccines against Neisseria meningitidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Immunologic response of man to group B meningococcal polysaccharide vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Characterization of an antibody depletion assay for analysis of bactericidal antibody specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

Immunogenicity of a Single Dose of Meningococcal Group C Conjugate Vaccine Given at 3 Months of Age to Healthy Infants in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

The Changing Epidemiology of Meningococcal Disease in the United States, 1992–1996

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

New Zealand Epidemic Strain Meningococcal B Outer Membrane Vesicle Vaccine in Children Aged 16???24 Months

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2012.03085.X

10.1111/J.1365-3156.2012.03085.X

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

22947250